Human adipose-derived stem cell adipogenesis inducesparacrine regulation of the invasive ability of MCF-7 human breast cancer cells in vitro

Experimental and Therapeutic Medicine

Volumn 6, Issue 4, 2013, Pages 937-942

  Zhao, Yang ^a   Gao, Jianhua ^a   Lu, Feng ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Cytokine; Human adipose derived stem cells; Human breast cancer cells; Invasive; Metalloproteinase; Paracrine

Indexed keywords

CD34 ANTIGEN; CD45 ANTIGEN; ENDOGLIN; GELATINASE A; HERMES ANTIGEN; LEPTIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RIBOSOME INACTIVATING PROTEIN 2; UROKINASE; VASCULOTROPIN;

ADIPOGENESIS; ADIPOSE DERIVED STEM CELL; ADIPOSE TISSUE; ARTICLE; BREAST CANCER; CELL DIFFERENTIATION; CELL INVASION; CELL MATURATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HORMONAL REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MORPHOLOGICAL ADAPTATION; OPTICAL DENSITY; OSTEOBLAST; PARACRINE SIGNALING; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84883232383     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1237     Document Type: Article

References (26)

1. Bucky LP and Percec I: The science of autologous fat grafting: views on current and future approaches to neoadipogenesis. Aesthet Surg J 28: 313-321, 2008.
2. Hsu VM, Stransky CA, Bucky LP and Percec I: Fat grafting's past, present, and future: why adipose tissue is emerging as a critical link to the advancement of regenerative medicine. Aesthet Surg J 32: 892-899, 2012.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
4. Trojahn Kølle SF, Oliveri RS, Glovinski PV, Elberg JJ, Fischer Nielsen A and Drzewiecki KT: Importance of mesenchymal stem cells in autologous fat grafting: a systematic review of existing studies. J Plast Surg Hand Surg 46: 59-68, 2012.
5. Philips BJ, Marra KG and Rubin JP: Adipose stem cell-based soft tissue regeneration. Expert Opin Biol Ther 12: 155-163, 2012.
6. Watanabe M, Inukai K, Katagiri H, Awata T, Oka Y and Katayama S: Regulation of PPAR gamma transcriptional activity in 3T3-L1 adipocytes. Biochem Biophys Res Commun 300: 429-436, 2003.
7. Moldes M, Zuo Y, Morrison RF, et al: Peroxisome proliferator activated receptor gamma suppresses Wnt/beta-catenin signalling during adipogenesis. Biochem J 376: 607-613, 2003.
8. Wu Z, Rosen ED, Brun R, et al: Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell 3: 151-158, 1999.
9. Prusty D, Park BH, Davis KE and Farmer SR: Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferator-activated receptor gamma (PPARgamma) and C/EBPalpha gene expression during the differentiation of 3T3-L1 preadipocytes. J Biol Chem 277: 46226-46232, 2002.
10. Crowe DL and Chandraratna RA: A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res 6: R546-R555, 2004.
11. Yadav S, Anbalagan M, Shi Y, Wang F and Wang H: Arsenic inhibits the adipogenic differentiation of mesenchymal stem cells by down-regulating peroxisome proliferator-activated receptor gamma and CCAAT enhancer-binding proteins. Toxicol In Vitro 27: 211-219, 2013.
12. Lo Furno D, Graziano AC, Caggia S, et al: Decrease of apoptosis markers during adipogenic differentiation of mesenchymal stem cells from human adipose tissue. Apoptosis 18: 578-588, 2013.
13. Dong YW, Wang XP and Wu K: Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition. World J Gastroenterol 15: 441-448, 2009.
14. Fenner MH and Elstner E: Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer. Expert Opin Investig Drugs 14: 557-568, 2005.
15. Pellikainen JM and Kosma VM: Activator protein-2 in carcinogenesis with a special reference to breast cancer - a mini review. Int J Cancer 120: 2061-2067, 2007.
16. Zuk PA, Zhu M, Mizuno H, et al: Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7: 211-228, 2001.
17. Wieczorek E, Reszka E, Gromadzinska J and Wasowicz W: Genetic polymorphism of matrix metalloproteinases in breast cancer. Neoplasma 59: 237-247, 2012.
18. Velinov N, Poptodorov G, Gabrovski N and Gabrovski S: The role of matrix metalloproteinases in the tumor growth and metastasis. Khirurgiia (Sofiia) 1: 44-49, 2010 (In Bulgarian).
19. Kunigal S, Lakka SS, Gondi CS, Estes N and Rao JS: RNAi mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer 121: 2307-2316, 2007.
20. Lakka SS, Gondi CS, Dinh DH, et al: Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas. J Biol Chem 280: 21882-21892, 2005.
21. Tang L and Han X: The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomed Pharmacother 67: 179-182, 2013.
22. Holst-Hansen C, Johannessen B, Hoyer-Hansen G, Romer J, Ellis V and Brunner N: Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 14: 297-307, 1996.
23. Wang XF, Zhou QM, Du J, Zhang H, Lu YY and Su SB: Baicalin suppresses migration, invasion and metastasis of breast cancer via p38MAPK signaling pathway. Anticancer Agents Med Chem 13: 923-931, 2013.
24. Jezierska A and Motyl T: Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit 15: RA32-RA40, 2009.
25. Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID and Sogayar C: Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 9: 20, 2009.
26. Perera RJ, Marcusson EG, Koo S, et al: Identification of novel PPARgamma target genes in primary human adipocytes. Gene 369: 90-99, 2006.